The differential and effective cytotoxic activation of Jurkat cells by preclinical E09 and CH11 antibodies underscores the need for the next generation of Fas agonists with reverse tumor activation profiles with optimal T-cell safety. The gene discussed is FAS; the disease is neoplasm.